

Mohammad Shadab Siddiqui

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1145468/publications.pdf>

Version: 2024-02-01

72
papers

3,389
citations

201385

27
h-index

155451

55
g-index

73
all docs

73
docs citations

73
times ranked

4078
citing authors

#	ARTICLE	IF	CITATIONS
1	Vibration-Controlled Transient Elastography to Assess Fibrosis and Steatosis in Patients With Nonalcoholic Fatty Liver Disease. <i>Clinical Gastroenterology and Hepatology</i> , 2019, 17, 156-163.e2.	2.4	322
2	The presence and severity of nonalcoholic steatohepatitis is associated with specific changes in circulating bile acids. <i>Hepatology</i> , 2018, 67, 534-548.	3.6	266
3	<p>Obesity paradox in cardiovascular disease: where do we stand?</p>. <i>Vascular Health and Risk Management</i> , 2019, Volume 15, 89-100.	1.0	234
4	Fecal Microbial Transplant Capsules Are Safe in Hepatic Encephalopathy: A Phase 1, Randomized, Placeboâ€Controlled Trial. <i>Hepatology</i> , 2019, 70, 1690-1703.	3.6	196
5	Performance characteristics of vibrationâ€controlled transient elastography for evaluation of nonalcoholic fatty liver disease. <i>Hepatology</i> , 2018, 67, 134-144.	3.6	192
6	Severity of Nonalcoholic Fatty Liver Disease and Progression to Cirrhosis Are Associated With Atherogenic Lipoprotein Profile. <i>Clinical Gastroenterology and Hepatology</i> , 2015, 13, 1000-1008.e3.	2.4	164
7	Diagnostic Accuracy of Noninvasive Fibrosis Models to Detect Change in Fibrosis Stage. <i>Clinical Gastroenterology and Hepatology</i> , 2019, 17, 1877-1885.e5.	2.4	145
8	Case definitions for inclusion and analysis of endpoints in clinical trials for nonalcoholic steatohepatitis through the lens of regulatory science. <i>Hepatology</i> , 2018, 67, 2001-2012.	3.6	125
9	Clinical characteristics, surveillance, treatment allocation, and outcomes of non-alcoholic fatty liver disease-related hepatocellular carcinoma: a systematic review and meta-analysis. <i>Lancet Oncology</i> , The, 2022, 23, 521-530.	5.1	116
10	Long-term Outcomes in Patients Undergoing Liver Transplantation for Nonalcoholic Steatohepatitis-Related Cirrhosis. <i>Transplantation</i> , 2017, 101, 1867-1874.	0.5	112
11	Gene Expression Predicts Histological Severity and Reveals Distinct Molecular Profiles of Nonalcoholic Fatty Liver Disease. <i>Scientific Reports</i> , 2019, 9, 12541.	1.6	106
12	Proton Pump Inhibitor Initiation and Withdrawal affects Gut Microbiota and Readmission Risk in Cirrhosis. <i>American Journal of Gastroenterology</i> , 2018, 113, 1177-1186.	0.2	98
13	An Observational Data Meta-analysis on the Differences in Prevalence and Risk Factors Between MAFLD vs NAFLD. <i>Clinical Gastroenterology and Hepatology</i> , 2023, 21, 619-629.e7.	2.4	90
14	Impact of obeticholic acid on the lipoprotein profile in patients with non-alcoholic steatohepatitis. <i>Journal of Hepatology</i> , 2020, 72, 25-33.	1.8	88
15	Coronary artery disease in decompensated patients undergoing liver transplantation evaluation. <i>Liver Transplantation</i> , 2018, 24, 333-342.	1.3	78
16	Preserved hemostatic status in patients with non-alcoholic fatty liver disease. <i>Journal of Hepatology</i> , 2016, 65, 980-987.	1.8	72
17	A Meta-Analysis on the Global Prevalence, Risk factors and Screening of Coronary Heart Disease in Nonalcoholic Fatty Liver Disease. <i>Clinical Gastroenterology and Hepatology</i> , 2022, 20, 2462-2473.e10.	2.4	59
18	Microbial functional change is linked with clinical outcomes after capsular fecal transplant in cirrhosis. <i>JCI Insight</i> , 2019, 4, .	2.3	49

#	ARTICLE	IF	CITATIONS
19	Non-alcoholic fatty liver disease increases risk of carotid atherosclerosis and ischemic stroke: An updated meta-analysis with 135,602 individuals. <i>Clinical and Molecular Hepatology</i> , 2022, 28, 483-496.	4.5	49
20	The Impact of Coronary Artery Disease and Statins on Survival After Liver Transplantation. <i>Liver Transplantation</i> , 2019, 25, 1514-1523.	1.3	46
21	The etiology of cirrhosis is a strong determinant of brain reserve: A multimodal magnetic resonance imaging study. <i>Liver Transplantation</i> , 2015, 21, 1123-1132.	1.3	45
22	Utilization of aspirin and statin in management of coronary artery disease in patients with cirrhosis undergoing liver transplant evaluation. <i>Liver Transplantation</i> , 2018, 24, 872-880.	1.3	43
23	Harnessing Muscleâ€œLiver Crosstalk to Treat Nonalcoholic Steatohepatitis. <i>Frontiers in Endocrinology</i> , 2020, 11, 592373.	1.5	42
24	A Phase 2 Double Blinded, Randomized Controlled Trial of Saroglitazar in Patients With Nonalcoholic Steatohepatitis. <i>Clinical Gastroenterology and Hepatology</i> , 2021, 19, 2670-2672.	2.4	41
25	Performance of nonâ€œinvasive models of fibrosis in predicting mild to moderate fibrosis in patients with nonâ€œalcoholic fatty liver disease. <i>Liver International</i> , 2016, 36, 572-579.	1.9	38
26	Relation of Hepatic Fibrosis in Nonalcoholic Fatty Liver Disease to Left Ventricular Diastolic Function and Exercise Tolerance. <i>American Journal of Cardiology</i> , 2019, 123, 466-473.	0.7	36
27	Metabolic Associated Fatty Liver Disease Increases the Risk of Systemic Complications and Mortality. A Meta-Analysis and Systematic Review of 12â€œ%620â€œ%736 Individuals. <i>Endocrine Practice</i> , 2022, 28, 667-672.	1.1	34
28	Diagnostic Performance of Vibration-Controlled Transient Elastography in Liver Transplant Recipients. <i>Clinical Gastroenterology and Hepatology</i> , 2021, 19, 367-374.	2.4	33
29	Antidiabetic Medications for Type 2 Diabetics with Nonalcoholic Fatty Liver Disease: Evidence From a Network Meta-Analysis of Randomized Controlled Trials. <i>Endocrine Practice</i> , 2022, 28, 223-230.	1.1	31
30	The relationship between coronary artery disease and cardiovascular events early after liver transplantation. <i>Liver International</i> , 2019, 39, 1363-1371.	1.9	30
31	Treatment of HCV in the Department of Corrections in the Era of Oral Medications. <i>Journal of Correctional Health Care</i> , 2018, 24, 127-136.	0.2	29
32	Small Dense Lowâ€œDensity Lipoprotein Cholesterol Predicts Cardiovascular Events in Liver Transplant Recipients. <i>Hepatology</i> , 2019, 70, 98-107.	3.6	29
33	Outcomes of Nonalcoholic Steatohepatitis After Liver Transplantation: An Updated Meta-Analysis and Systematic Review. <i>Clinical Gastroenterology and Hepatology</i> , 2023, 21, 45-54.e6.	2.4	29
34	Nonalcoholic Steatohepatitis (NASH) Is Associated with a Decline in Pancreatic Beta Cell (β -Cell) Function. <i>Digestive Diseases and Sciences</i> , 2015, 60, 2529-2537.	1.1	28
35	Non-alcoholic fatty liver disease association with structural heart, systolic and diastolic dysfunction: a meta-analysis. <i>Hepatology International</i> , 2022, 16, 269-281.	1.9	23
36	Validation of the accuracy of the FASTâ„¢ score for detecting patients with at-risk nonalcoholic steatohepatitis (NASH) in a North American cohort and comparison to other non-invasive algorithms. <i>PLoS ONE</i> , 2022, 17, e0266859.	1.1	20

#	ARTICLE	IF	CITATIONS
37	Randomized Controlled Trial of a Leucineâ€Metforminâ€Sildenafil Combination (NSâ€0200) on Weight and Metabolic Parameters. <i>Obesity</i> , 2019, 27, 59-67.	1.5	18
38	Current and Emerging Therapies for Non-alcoholic Fatty Liver Disease. <i>Drugs</i> , 2019, 79, 75-84.	4.9	17
39	The role of noninvasive biomarkers in diagnosis and risk stratification in nonalcoholic fatty liver disease. <i>Endocrinology, Diabetes and Metabolism</i> , 2020, 3, e00127.	1.0	15
40	Adherence to Recommended Inpatient Hepatic Encephalopathy Workup. <i>Journal of Hospital Medicine</i> , 2019, 14, 157-160.	0.7	15
41	A Metaâ€Analysis and Systematic Review on the Global Prevalence, Risk Factors, and Outcomes of Coronary Artery Disease in Liver Transplantation Recipients. <i>Liver Transplantation</i> , 2022, 28, 689-699.	1.3	15
42	Metaâ€analysis: analysis of mechanistic pathways in the treatment of <sc>nonâ€alcoholic</sc> steatohepatitis. Evidence from a Bayesian network <sc>metaâ€analysis</sc>. <i>Alimentary Pharmacology and Therapeutics</i> , 2022, 55, 1076-1087.	1.9	15
43	The Interplay Between Nonalcoholic Fatty Liver Disease and Atherosclerotic Heart Disease. <i>Hepatology</i> , 2019, 69, 1372-1374.	3.6	14
44	Factors Impacting Survival in Those Transplanted for NASH Cirrhosis: Data From the NailNASH Consortium. <i>Clinical Gastroenterology and Hepatology</i> , 2023, 21, 445-455.e2.	2.4	13
45	Prevalence and Severity of Nonalcoholic Fatty Liver Disease Among Caregivers of Patients With Nonalcoholic Fatty Liver Disease Cirrhosis. <i>Clinical Gastroenterology and Hepatology</i> , 2019, 17, 2132-2133.	2.4	12
46	The Relationship Between Hypoadiponectinemia and Cardiovascular Events in Liver Transplant Recipients. <i>Transplantation</i> , 2019, 103, 2323-2328.	0.5	12
47	Progression to Cirrhosis Leads to Improvement in Atherogenic Milieu. <i>Digestive Diseases and Sciences</i> , 2021, 66, 263-272.	1.1	11
48	A systematic review and meta-analysis on the impact of pre-existing and new-onset atrial fibrillation on outcomes before and after liver transplantation. <i>Digestive and Liver Disease</i> , 2022, 54, 614-621.	0.4	11
49	Office-Based Weight Loss Counseling Is Ineffective in Liver Transplant Recipients. <i>Digestive Diseases and Sciences</i> , 2020, 65, 639-646.	1.1	9
50	Differential fuel utilization in liver transplant recipients and its relationship with nonâ€alcoholic fatty liver disease. <i>Liver International</i> , 2022, 42, 1401-1409.	1.9	8
51	Clopidogrel Responsiveness in Patients With Decompensated Cirrhosis of the Liver Undergoing Pre-Transplant PCI. <i>JACC: Cardiovascular Interventions</i> , 2020, 13, 661-663.	1.1	7
52	Association Between Lipoprotein Particles and Atherosclerotic Events in Nonalcoholic Fatty Liver Disease. <i>Clinical Gastroenterology and Hepatology</i> , 2021, 19, 2202-2204.	2.4	7
53	Range of Normal Serum Aminotransferase Levels in Liver Transplant Recipients. <i>Transplantation Proceedings</i> , 2019, 51, 1895-1901.	0.3	6
54	Review article: the impact of liverâ€directed therapies on the atherogenic risk profile in nonâ€alcoholic steatohepatitis. <i>Alimentary Pharmacology and Therapeutics</i> , 2020, 52, 619-636.	1.9	6

#	ARTICLE	IF	CITATIONS
55	Atherogenic Dyslipidemia After Liver Transplantation: Mechanisms and Clinical Implications. <i>Liver Transplantation</i> , 2021, 27, 1326-1333.	1.3	6
56	A meta-analysis of the cumulative incidence, risk factors, and clinical outcomes associated with chronic kidney disease after liver transplantation. <i>Transplant International</i> , 2021, 34, 2524-2533.	0.8	6
57	A Diagnostic Test Meta-Analysis Evaluating Imaging-Based and Blood Biomarker-Based Assessment Tools for Fibrosis After Liver Transplantation. <i>Liver Transplantation</i> , 2022, 28, 659-669.	1.3	6
58	Changes of in vitro potency of anticoagulant drugs are similar between patients with cirrhosis due to alcohol or non-alcoholic fatty liver disease. <i>Thrombosis Research</i> , 2017, 150, 41-43.	0.8	5
59	Glomerular filtration rate early after liver transplantation independently predicts atherosclerotic events. <i>Liver Transplantation</i> , 2022, 28, 1186-1195.	1.3	4
60	Endoscopic Cyanoacrylate Injection with Post-injection Audible Doppler Assessment of Gastric Varices: A Single-Institution Experience. <i>Digestive Diseases and Sciences</i> , 2017, 62, 3091-3099.	1.1	3
61	Implications of Nonalcoholic Steatohepatitis as the Cause of End-Stage Liver Disease Before and After Liver Transplant. <i>Gastroenterology Clinics of North America</i> , 2020, 49, 165-178.	1.0	3
62	Early laboratory values after liver transplantation are associated with anastomotic biliary strictures. <i>Annals of Hepato-biliary-pancreatic Surgery</i> , 2022, 26, 76-83.	0.1	2
63	Interplay Between Dyslipidemia, Atherogenic Lipoproteins, and Residual Atherogenic Risk in Liver Transplant Recipients. <i>Clinical Gastroenterology and Hepatology</i> , 2023, 21, 1660-1662.e1.	2.4	2
64	Editorial: ascitic cholesterol—is it superior to serum ascites albumin gradient?. <i>Alimentary Pharmacology and Therapeutics</i> , 2019, 49, 814-815.	1.9	1
65	Editorial: targeting aberrant hepatic inflammation for treatment of non-alcoholic steatohepatitis. <i>Alimentary Pharmacology and Therapeutics</i> , 2022, 55, 483-484.	1.9	1
66	Performance of Vibration-Controlled Transient Elastography and Clinical Prediction Models In Liver Transplant Recipients. <i>Clinical Gastroenterology and Hepatology</i> , 2022, , .	2.4	1
67	Non-alcoholic Fatty Liver Disease in Non-obese Patients. <i>Current Hepatology Reports</i> , 2017, 16, 382-390.	0.4	0
68	Reply. <i>Liver Transplantation</i> , 2018, 24, 978-979.	1.3	0
69	Reply. <i>Hepatology</i> , 2020, 71, 401-402.	3.6	0
70	Nonalcoholic Fatty Liver Disease. <i>Gastroenterology Clinics of North America</i> , 2020, 49, xiii-xiv.	1.0	0
71	Sex Differences in Vascular Endothelial Function After Liver Transplant. <i>FASEB Journal</i> , 2022, 36, .	0.2	0
72	Weight Gain, Fibroblast Growth Factor-23, and Vascular Function in Liver Transplant Recipients. <i>FASEB Journal</i> , 2022, 36, .	0.2	0